West African Emerging Infectious Disease Research Center (WA-EIDRC)

西非新发传染病研究中心 (WA-EIDRC)

• 批准号: 10653441
• 负责人: Kristian Graugaard Andersen
• 金额: $ 184.89万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-09 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10653441
• 关键词: 2019-nCoV; Acute; African; Award; COVID-19; COVID-19 pandemic; COVID-19 patient; Cessation of life; Detection; Diagnostic tests; Drug resistance; Emerging Communicable Diseases; Epidemiology; Evolution; Functional disorder; Funding; Goals; Immune; Immune response; Incidence; Incidence Study; Individual; Infectious Diseases Research; Lead; Oral; Parents; Pathogenesis; Paxlovid; Prevalence; Public Health; Rapid diagnostics; Reagent; Reporting; SARS-CoV-2 infection; Serology; Symptoms; System; Testing; Therapeutic; Viral Load result; Virus; Work; base; cohort; computerized tools; diagnostic assay; drug development; emerging pathogen; experience; improved; metagenomic sequencing; pathogen; programs; surveillance study; symptomatology; transmission process; treatment duration

PROJECT SUMMARY With the increasing use of oral antiviral treatments for acute SARS-CoV-2 infection, there have been multiple reports of symptom and viral load rebound after the prescribed treatment course. The most prescribed oral antiviral is Paxlovid, and while it has become a component of test-to-treat programs, there are no incidence or prevalence numbers on Paxlovid (symptomatologic and/or virologic) rebound after the five-day treatment course. Further, the connection between symptoms, viral load rebound, and immune correlates is unknown as well. This is of utmost urgence from a public health standpoint, given the possibility of the individual remaining infectious despite Paxlovid treatment and concerns about the potential development of drug resistance. Therefore, with additional funding we propose to study the incidence, prevalence, symptomatology, virus evolution, and immune correlates of COVID-19 cases who rebound after completion of Paxlovid treatment.

项目总结 随着口服抗病毒治疗对急性SARS-CoV-2感染的使用越来越多， 已有多份报告称，在服用了处方后，症状和病毒载量反弹 治疗疗程。处方最多的口服抗病毒药物是帕昔洛韦，虽然它已经成为一种 测试治疗计划的组成部分，没有发病率或患病率数字 帕昔洛韦(症状和/或病毒学)在five-day疗程后反弹。 此外，症状、病毒载量反弹和免疫相关性之间的联系是 也是未知的。从公共卫生的角度来看，这是最紧迫的，因为 尽管接受帕昔洛韦治疗和担忧，个人仍具有传染性的可能性 关于抗药性的潜在发展。因此，有了额外的资金，我们 建议研究发病率、流行率、症状、病毒演变和免疫 新冠肺炎患者帕昔洛韦治疗后反弹的相关因素。